All In Biotech

Drug Trial Radar · NCT04975204

A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors

A Phase I Clinical Trial Evaluating the Tolerance and Pharmacokinetics of TQB3909 Tablets in Patients With Relapsed or Refractory Advanced Malignant Tumors

Last checked: Nov 19, 2026Latest source record: Mar 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

126

Planned (sponsor's estimate)

Start

Feb 18, 2022

Primary completion

Dec 2022

Study completion Aug 2024

Sponsor

Sponsor type
Industry
First posted
Jul 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TQB3909 is an inhibitor targeting at B-cell lymphoma (BCL)-2 protein. By binding to BCL-2 protein, TQB3909 releases Pro apoptotic proteins such as BCL-2-Anatagonist/Killer 1(BAK), BCL-2 associated X (BAX) protein and BCL-2 associated death (BAD) protein, promotes the release of cytochrome c from mitochondria, phosphatidylserine eversion, stimulates caspase 3 / 7 activity and caspase 3 / 9 cleavage, and induces apoptosis.

Conditions

  • Advanced Malignant Tumor

Interventions

  • TQB3909 TabletsDrug

    TQB3909 is an inhibitor targeting BCL-2 protein

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity(DLT)Time frame: up to 18 months
  2. Recommended Phase II Dose (RP2D)Time frame: up to 18 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Jiangsu Provincial People's Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.